Tag : TRASTUZUMAB DERUXTECAN

Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer is the most prevalent subtype of the disease, accounting for approximately 70% of all cases. While first-line endocrine-based regimens demonstrate considerable efficacy, later-line single-agent chemotherapy has limited effectiveness, highlighting a significant unmet need.